Bioterrorism Projects Boost US Research Budget

For the US government's fiscal year 2003, which begins Oct. 1 this year, President George W. Bush has requested a budget of $27.3 billion for the National Institutes of Health, a 15.7% increase of $3.7 billion, the largest single-year boost in history. With a supportive Congress, this will complete the goal of doubling the NIH budget over the five-year period beginning in 1998. About $1.5 billion, or 40%, of next year's increase is focused on bioterrorism-related research and infrastructure, bri

Written byTed Agres
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

"An effective biodefense will require a long-term strategy and significant new investment in the US health care system," Bush said in announcing the budget in February. "NIH will lead a partnership with industry, academia, and government agencies dedicated to understanding the pathogenesis of potential bioterrorism agents and to translating this knowledge into required medical products."

Most of NIH's increase is earmarked for the National Institute of Allergy and Infectious Diseases (NIAID), which will see its budget jump 57%, from $2.5 billion to nearly $4.0 billion. The next biggest increase is for the National Cancer Institute (NCI), which would grow by 12%, from $4.2 billion to $4.7 billion.

Anthony S. Fauci, NIAID director, says his institute has developed the following strategic plan to allocate the $1.7 billion in bioterror funding:

NIH officials defend the emphasis on bioterrorism. "We have essentially what is almost a national emergency to get ourselves prepared against ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies